Having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole (A61K31/41)

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex

New cc-1065 analogs and their conjugates // 2628069
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula or a pharmaceutically acceptable salt thereof, wherein DB is a DNA-binding group and is DB6 group ; R1 is chlorine; R2, R2', R3, R3', R4, R4', R12 and R19are H; X2 is selected from C(R14)(R14'), where R14' has the same value as defined for R7' and is independently selected, and R14' and R7' are absent, which gives a double bond between the atoms carrying R7' and R14'; R5, R6 and R7 are independently selected from H, R, where Re are selected from C1Alkyl, and R5'+R6', are absent, which gives a double bond between the atoms carrying R5 and R6, and/or R6 and R7, and/or R7 and R14 respectively; X1 is selected from O; X3 is selected from S, N, and NR15; X4 is selected from N and CR16; X5 is selected from O; X6* is selected from CR11; X7 is selected from CR8, N; X8 is selected from CR9, N; X9* is selected from CR10; X10* is selected from CR20; X11* is selected from C; X7* and X8* have the same values as those defined for X7 and X8 respectively, and are chosen independently; X34 is selected from C; annular atom B in X11* in DB6 is connected to the ring atom of ring A, so that ring A and ring B in DB6 are directly connected through a direct link; fig. implies that the said bond can be a or a non-cumulated direct bond, optionally delocalized, double bond; R8, R9, R10, R11, R15, R16, R20 are each independently selected from H, N(Rh)C(O)Ri, where Rh, Ri are independently selected from H and optionally substituted C6 aryl, one optional substituent in Ri is -OH or -NH2; a is 0 and b is 1. The invention relates to a pharmaceutical composition for tumour treatment or prevention for a mammal, comprising a therapeutically effective amount of formula (I) compound and a pharmaceutically acceptable carrier.EFFECT: DNA-alkylating agent SS-1065 analogues.6 cl, 13 dwg, 1 tbl, 23 ex

9-benzyl-2-biphenylimidazo[1,2-a]benzimidazole and pharmaceutically acceptable salts thereof that express properties of destroyers of transversal cross-links of glycosylated proteins // 2627769
FIELD: pharmacology.SUBSTANCE: invention relates to new 9-benzyl-2-biphenylimidazo[1,2-a]benzimidazole (I) and pharmaceutically acceptable salts thereof.EFFECT: imidazobenzimidazole derivatives having the property of destroyers of transversal cross-links of glycosylated proteins.3 cl, 2 dwg, 1 tbl, 1 ex

Crystalline forms of 1-(3-tret-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyetil)-1h-indasol-5-yloxy)benzyl) hydrochloride urea // 2627702
FIELD: pharmacology.SUBSTANCE: invention relates to a crystalline polymorphic Form B of the hydrochloride salt of 1-(3-t-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl) urea, which is characterized by the presence of peaked diffraction peaks (degrees 2θ at ± 0.3) at about 12.3, 13.0, 15.9, 16.9 and 17.6 and to a pharmaceutical composition for proliferative disorders treatment comprising the said polymorphic Form B. The invention also relates to a method for proliferative diseases treatment with the claimed pharmaceutical composition, pharmaceutical composition and method application for preparation of the said polymorphic Form B.EFFECT: increased efficiency of treatment.89 cl, 7 dwg, 23 tbl, 10 ex

Formulations of 2-iminobiotine and use thereof // 2627460
FIELD: pharmaceutics.SUBSTANCE: present invention relates to 2-iminobiotine pharmaceutical aqueous composition, having pH from 3 to 7 and containing 1 mg/ml or more of 2-iminobiotine and from 2.5 to 40 % of substituted beta-cyclodextrin, wherein said substituted beta-cyclodextrin is selected from sulfobutylether-beta-cyclodextrin (SBE-CD) and hydroxypropyl-beta-cyclodextrin.EFFECT: invention provides creation of aqueous solution of 2-iminobiotine with high content of 2-iminobiotine (higher solubility of 2-iminobiotine), which is ensured by introduction of substituted beta-cyclodextrin into disclosed composition or citric acid/citrate buffer to ensure solution pH from 3 to 7.19 cl, 14 ex, 27 tbl, 1 dwg
ethod for anesthetic maintenance during radical surgery for cancer patients // 2627289
FIELD: medicine.SUBSTANCE: after patient admission to the operating room dexmedetomidine administration starts at a dose of 0.6-0.8 mcg/kg/h. Then epidural space catheterization is perform lying on the side. Analgesic mixture administration starts at a rate of 5 ml/hour and continued throughout the operation. During denitrogenation, intravenous dexmedetomidine sedation is performed at an dose of 0.6-0.8 mcg/kg/hr, after repeated denitrogenation and transition to closed circuit, oxygen supply is stopped. The breathing bag is completely emptied, then Xe is fed rapidly, once filling the breathing bag, ventilation by pure Xe flow of 150-300 ml per minute is begun under the control of FiO2 to reduce the oxygen concentration in the breathing circuit to 40% and Xe concentration to 60%, and then oxygen is supplied at a dose of 4 ml/kg, maintaining the balance in the ratio of Xe:O2 60:40. Xe flow is reduced to 0-100 ml/min intravenous administering of dexmedetomidine is continued throughout the operation at a dose of 0.3-0.6 mcg/kg/hr. Prior to surgical wound suturing Xe supply is stopped. After surgery, anesthesia machine is converted to a semi-open circuit, oxygen flow is increased to 5 l/min, sodium sugammadex is introduced at the rate of used bromide rocuronium. The patient extubated, in the early postoperative period analgesic mixture administration is continued at a rate of 5 ml/hr and intravenous dexmedetomidine administration is continued at a dose of 0.3-0.6 mcg/kg/h under the control of sedation level and hemodynamics.EFFECT: method allows to obtain an efficient multimodal anesthetic protection, reduce xenon and narcotic analgesics consumption during extended and highly-traumatic cancer surgery.2 ex
1,2,4-triazol-3-ylthioglycolic acid amide with antiviral activity or its pharmaceutically acceptable salts, pharmaceutical compositions, and their application for flu treatment and prevention // 2626003
FIELD: pharmacology.SUBSTANCE: invention relates to 2-[5-(2-chloro-4-methylphenyl)-4-phenyl-4H-[1,2,4]trisol-3-ylmercapto]-N-(3,5-dimethylphenyl)acetamide with the structural formula (I): . The invention also relates to compound application, to a pharmaceutical composition, to a dosage form, to a method for flu prevention or treatment.EFFECT: new compound is obtained that has selective antiviral activity against strains of influenza A.10 cl, 1 dwg, 1 tbl, 8 ex

New pyrazole derivative // 2625790
FIELD: pharmacology.SUBSTANCE: in particular, invention relates to a compound represented by the following general formula (I): [wherein Ar1 is 2-methoxy-4-(2-pyridylmethoxy)phenyl, etc. and Ar2 is 1H-indole-6-yl group, etc.] or to salt thereof.EFFECT: increased efficiency of treatment.19 cl, 4 dwg, 1 tbl, 112 ex
Application of pyrazole derivative in treatment of acute attacks of chronic obstructive pulmonary disease // 2625762
FIELD: pharmacology.SUBSTANCE: 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof are applied. Application of a single dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable derivative thereof, using 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide in the drug manufacture, method of treating acute attacks of chronic obstructive pulmonary disease, a drug for oralinjection comprising 3-[5-amino-4-(3-cyanobenzoyl)-pirasol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof are also proposed.EFFECT: treatment of acute attacks of chronic obstructive pulmonary disease.17 cl, 5 tbl, 1 ex
Combined drug of anxiolithic, stress-protector, nootropic and antioxidant action // 2625754
FIELD: pharmacology.SUBSTANCE: invention is a combined drug of anxiolytic, stress-protective, nootropic and antioxidant action containing tryptophan, characterised by additional content of tiotriazoline at a quantitative ratio: tryptophan ranging from 1 to 7 wt parts per 1 wt part of thiotriazoline.EFFECT: agent has a higher anxiolytic and antioxidant activity compared to the known agents and has additional nootropic and stress-protective action.3 cl, 5 tbl, 2 ex
Application of rac-n-{4-[(2-ethoxy-3-octadecyloxy)propyl] oxycarbonylbutyl}-n-methyl-imidazoline iodide as a multikinase inhibitor // 2625749
FIELD: pharmacology.SUBSTANCE: application of rac-n-{4-[(2-ethoxy-3-octadecyloxy)propyl] oxycarbonylbutyl}-n-methyl-imidazoline iodide based on the identified activity as neoplastic cells Ins-R, MET, Src and Pim-1 protein kinases inhibitor.EFFECT: ability of the said compound to inhibit all the said protein kinases that mediate the carcinogenesis of those types of tumour cells in which they are actively expressed, unlike edelphosphine.1 tbl, 1 dwg, 2 ex
8-carbamoyl-2-(2,3-di-substituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for cancer treatment // 2625315
FIELD: pharmacology.SUBSTANCE: invention relates to organic chemistry, namely a heterocyclic compound of formula (I) or to a therapeutically acceptable salt thereof, where X is benzo[d]thiazolyl, thiazolo[5,4-b]pyridinyl, thiazolo[4,5-c]pyridinyl, imidazo[1,2-a]pyridinyl, thiazolo[5,4-c]pyridinyl, thiazolo[4,5-b]pyridinyl, imidazo[1,2-a]pyrazinyl or imidazo[ 1,2-b]pyridazinyl; Y1 means pyrrolyl, pyrazolyl, triazolyl or pyridinyl; where Y1 is optionally substituted with 1 or 2 substituents independently selected from R5, CN and Cl; L1 is selected from (CR6R7)q, (CR6R7)s-O-(CR6R7)r, (CR6R7)s-S-(CR6R7)r, (CR6R7)s-S(O)2-(CR6R7)r and (CR6R7)s-NR6A-(CR6R7)r; Y2 means mono- or tricyclic C8-C10-cycloalkyl, spiro[2.5]octyl, spiro[3.5]nonyl, oxatricyclo[3.3.1.13,7]decyl or azabicyclo[3.2.1]octyl; where Y2 is optionally substituted with 1, 2 or 3 substituents independently selected from R8, OR8, SO2R8, CO(O)R8, OH and Br; Z1 is selected from , R1 and R3 are absent; R2 is deuterium or C1-C6-alkyl; R5 is C1-C6-alkyl; R6A is selected from hydrogen and C1-C6-alkyl; each R6 and R7 are hydrogen; R8 is selected from the group consisting of C1-C3-alkyl, morpholinyl and dioxydothiomorpholinyl; where R8, meaning C1-C6-alkyl, is optionally substituted with a substituent selected from R16, OR16, SO2R16 and NHR16; Rk is selected from C1-C6-alkyl, morpholinyl, cyclopropyl and C1-haloalkyl; R16 Is selected from C1-C4-alkyl, phenyl, morpholinyl and tetrahydropyranyl; where R16, meaning C1-C4-alkyl, is optionally substituted with 1 substituent selected from OCH3, OCH2CH2OCH3 and OCH2CH2NHCH3; q is 1 or 2; s, m and p is 0; r is 0 or 1; N is 0, 1, or 2. The invention also relates to specific compounds, pharmaceutical compositions based on these compounds and a method for treatment of these diseases.EFFECT: new heterocyclic compounds are obtained, that are useful for treatment of some cancers.16 cl, 3 tbl, 86 ex
Pharmaceutical antidiabetic composition based on (+)-cis-3-(1h-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane carboxylic acid // 2624872
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical antidiabetic composition based on (+)-cis-3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane carboxylic acid, characterized in that it comprises microcrystalline cellulose 102, Povidone K30, croscarmellose sodium, magnesium stearate and talc as pharmaceutically acceptable excipients.EFFECT: increased bioavailability of the formulation active agent.2 cl, 3 dwg, 4 ex
ethod for complex treatment of patients with inflammatory periodontal diseases // 2624867
FIELD: medicine.SUBSTANCE: antiseptic treatment of the oral cavity is performed. Then, dental deposits are removed ultrasonically and manually. After that, a periodontal bandage is applied to the gum area of the upper and lower jaws, containing metronidazole, anesthesin and larva extract of large wax moth as active ingredients, and dimethicone 1000, styrene-maleic anhydride copolymer, T-2 emulsifier, vaseline oil, Lutrol F-68, Kollidon CL-M, orange essential oil as an ointment basis and purified water at a certain ratio of components. The course of treatment for patients with gingivitis and light chronic generalized periodontitis (CGP) is 3 sessions, with medium CGP - 5 sessions, severe CGP - 7 sessions, conducted every other day. Additionally, the gingival margin is treated 2 times a day with a dental pencil. The pencil contains metronidazole, baktisubtil and 10% alcohol extract of large wax moth larvae and auxiliary substances: beeswax, emulsifier No. 1, methylparaben, paraffin, peach oil, low molecular weight polyethylene with a molecular weight of 500-5000, lutrol F-127 and cremophor RN-40.EFFECT: increased therapeutic effect due to regenerative, immunomodulating, anesthetic, antibacterial and antiviral action of complex drugs used.2 tbl, 4 ex
ethod of treatment of luminal subtype of breast cancer n1 in postmenopausal period // 2624370
FIELD: medicine.SUBSTANCE: for the treatment of the luminal subtype of breast cancer N1 in the postmenopausal period, estrogen receptors are determined, the total diameter of metastases D in axillary lymph nodes and the average number of metastatic cells K whose nuclei express estrogen receptors in them. If identifying 2≤D<10 mm and the value of K exceeding 1%, radiotherapy is carried out according to the chosen treatment regimen, and after its completion, combined administration of tamoxifen and a nonselective beta-blocker is carried out daily in therapeutic doses for 1-5 years. If D≥10 mm is detected and at a value of K≥33% consistently perform adjuvant chemotherapy with simultaneous subcutaneous administration of fragin at a daily dose of 2500 ME daily, then radiotherapy is performed according to the chosen treatment regimen, and then hormone therapy with aromatase inhibitor is carried out for 5-7 years. If D≥10 mm is detected and with a value of K<33%, concurrent chemoradiotherapy and hormone therapy are performed, concomitantly with chemotherapy subcutaneous injection of fragmine at a dose of 5000 ME daily, and as an hormone inhibitor, an aromatase inhibitor is used for 7-10 years.EFFECT: method provides an opportunity to undergo a shorter period of treatment, in some cases to preserve the ability to work during it, to save the patient from possible complications while ensuring high effectiveness of therapy.3 ex

5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide with antiviral activity, and method for production // 2624018
FIELD: pharmacology.SUBSTANCE: invention relates to the 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide having selective antiviral activity against influenza A virus and herpes simplex virus of the first type having the structural formula . The invention also relates to a process for amide preparation.EFFECT: new compound with antiviral activity is obtained.2 cl, 2 dwg, 3 ex
Oxazethydine derivatives, method for their production and their use in medicine and cosmetics // 2624011
FIELD: chemistry.SUBSTANCE: invention relates to a heterocyclic compound of formula (I) and its enantiomer where R1 is a cyclopropylmethyl group, and R2 represents a methyl group; or R1 represents a 4-hydroxybutyl group, and R2 represents a hydrogen atom. The invention also relates to use of a formula compound (I) or compositions on the basis thereof, pharmaceutical compositions and cosmetic compositions based on compounds of formula (I).EFFECT: obtained new compound is useful in the treatment of pigmentation disorders and inflammatory or immune disorders.12 cl, 2 tbl, 3 ex
1-substituted-3-{[2-(3,5-di-tret-4-hydroxyphenyl)-2-oxoethyl]}-2aminobenzimidazolium bromides with antiplatelet and antioxidant properties // 2623439
FIELD: pharmacology.SUBSTANCE: invention relates to new benzimidazole derivatives of the general formula I , where (Ia) R = n-propyl, (Ib) R = allyl, which has antiplatelet and antioxidant properties.EFFECT: new benzimidazole derivatives are obtained, useful for myocardial infarction and stroke treatment.2 tbl, 2 ex

ethod for ptsd treatment // 2623209
FIELD: medicine.SUBSTANCE: for post-traumatic stress disorder treatment, an effective amount of vasopressin antagonist of formula or or is introduced.EFFECT: method provides effective correction of PTSD due to the selective action of these compounds on vasopressin receptors in the brain.11 cl, 238 ex, 2 dwg

Crystalline substance and pharmaceutical preparation containing it // 2622644
FIELD: pharmacology.SUBSTANCE: invention relates to a complex of crystalline luliconazole and short chain alcohol having 1 to 4 carbon atoms, wherein the content of short chain alcohol is from 262 to 7029 m.p. in relation to the total amount of complex .EFFECT: complex is used to treat fungus.7 cl, 1 dwg, 7 tbl, 12 ex
Azole derivatives // 2622639
FIELD: pharmacology.SUBSTANCE: invention relates to azole derivative of formula (I) or its pharmaceutically acceptable salt, wherein R1 is hydrogen atom or C1-5alkyl; R2 is hydrogen atom or C1-5alkyl; R3 is phenyl or pyridyl (where phenyl or pyridyl is optionally substituted with one or two fragments selected from the group consisting of C1-5alkoxy, halogen and trifluoromethyl atoms); each of R4 and R5, which can be the same or different, represent hydrogen atom or C1-5alkyl (where C1-5alkyl is optionally substituted with one fragment selected from the group consisting of hydroxy and C1-5alkoxy), or R4 and R5 together with nitrogen atom joining them form 4-7-membered saturated or unsaturated heterocycle, optionally compirsing one cyclic nitrogen, oxygen or sulfur atom, aside from the mentioned above joining nitrogen atom (where 4-7-membered saturated and unsaturated heterocycle is optionally substituted with one or two fragments, selected from the group consisting of hydroxy C1-5alkyl (where C1-5 alkyl is optionally substitued with one or two hydroxyl group), C1-5alkoxy, halogen atoms, cyano, C2-5alkanoyl, aminocarbonyl, mono-C1-5alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, trifluoromethyl, amino, mono-C1-5alkylamino, di-C1-5alkylamino and C2-5alkylamino, wherein the mentioned 4-7-membered saturated or unsaturated heterocycle optionally has C1-5alkylene fragment, joining two different cyclic carbon atoms), or form 2-oxa-6-azaspiro[3.3]hept-6-yl or 7-oxa-2-azaspiro[3.5]non-2-yl; azole cycle represented by formula (α) has any structure of group (II) formula, contained in invention formula, and wherein Ry is hydrogen atom or C1-5alkyl; X1 and X2 are such that: (i) if X1 means an ordinary link or fragment -CO-, X2 means -C1-5alkylene- or -O-C1-5alkylene-; and (ii) if X1 means a fragment -CONRx1-, X2means an ordinary link; Rx1 is hydrogen atom or C1-5alkyl; and cycle A is benzol cycle, pyridine cycle (where benzol cycle is optionally substituted with one or two fragments, selected from the group consisting of halogen atoms and C1-5alkoxy), 5-6-membered saturated or partly unsaturated heterocycle, containing one or two nitrogen atoms (where 5-6-membered saturated or unsaturated heterocycle is optionally substituted with one oxo group) or C3-7cycloalkane. The invention also relates to a pharmaceutical composition having antagonistic effect against V1b arginine-vasopressin receptor, and to agent for treating or preventing mood disorders, anxiety disorders or drug addiction, comprising azole derivative of formula (I) or its pharmaceutically acceptable salt as an active agent.EFFECT: azole derivative having antagonistic effect against V1b arginine-vasopressin receptor.12 cl, 22 tbl, 361 ex
Inhibitors of nonprilyzine // 2622288
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula , wherein R1 is selected from -OR7 and -NR8R9; R2 is H; X is -C1-9heteroaryl, selected from pyrazole, imidazole, triazole, benzotriazole, furan, tetrazole, pyrazine, thiophene, oxazole, isoxazole, thiazole, oxadiazole, pyridazine, pyridine, pyrimidine, benzoxazole, pyridylimidazole and pyridyltriazole; R3 is absent or is selected from H; Halogen; -C0-5alkylene-OH; -NH2; -C1-6alkyl; -CF3; -C3-7cycloalkyl; -C0-2alkylene-O-C1-6alkyl; -C(O)R20; -C0-1alkylene-COOR21; -C (O) NR22R23; -NHC(O)R24; =O; -NO2; -C(CH3) =N(OH); Phenyl optionally substituted with one or two groups independently selected from halogen, -OH, -CF3, -OCH3, -NHC(O)CH3 and phenyl; Naphthalenyl; Pyridinyl; Pyrazinyl; Pyrazolyl optionally substituted with methyl; Thiophenyl, optionally substituted by methyl or halogen; Furanyl; and -CH2-morpholinyl; and R3, when present, is attached to a carbon atom; R4 is absent or is selected from H; -HE; -C1-6alkyl; -C1-2alkylene-COOR35; -OCH2 O(O)CH (R36)NH2; -OCH2O(O)CH3; -CH2CH(OH)CH2OH; and phenyl or benzyl optionally substituted with 1 to 3 groups selected from halogen, -COOR35, -OCH3, -OCF3 and -SCF3; and R4, when present, is attached to a carbon or nitrogen atom; or R3 and R4 are taken together to form -phenylene-O- (CH2) 1-3- or -phenylene-O-CH2-CHOH-CH2-; A is 0 or 1; R5 is halogen; B is 0 or an integer of 1 to 3; Each R6 is independently selected from halogen, -OH, -CH3 and -OCH3; R7 is selected from H, -C1-8alkyl, -[(CH2)2O]1-3CH3, -C1-6alkylene-OC(O)R10, -C0-6alkylenemorpholinyl, -C1-6alkylene-SO2-C1-6alkyl and the structure of formula (a); R10 is -O-C3-7cycloalkyl; and R32 is -C1-6alkyl; R8 and R9 are H; R20, R21 and R35 are independently selected from H and -C1-6alkyl; R22 and R23 are independently selected from H, -C1-6alkyl, -CH2COOH, -(CH2)2OH, -(CH2)2OCH3, - (CH2)2SO2NH2, -(CH2)2N(CH3)2, -C0-1alkylene-C3-7-cycloalkyl and -(CH2)2-imidazolyl; or R22 and R23 are taken together to form a ring; R24 is selected from -C1-6alkyl; -C0-1alkylene-O-C1-6alkyl; Phenyl optionally substituted by halogen or -OCH3; and pyridinyl; and R36 is -CH (CH3) 2; and wherein the methylene linker on the biphenyl is optionally substituted with one or two -C1-6 alkyl groups; or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are prepared by combining a compound of formula with a compound of formula 2 to provide a compound of formula I; Where P1 is also H. Also, the invention relates to an intermediate of formula 1, wherein P1 is H. The compounds of formula (I) are intended for the preparation of a medicament or pharmaceutical composition having inhibitory activity against non-prolamin (NEP). (a).EFFECT: compounds that have a non-lysine inhibitory enzyme activity.28 cl, 61 tbl, 25 ex
Application of "triderm" for wound treatment and skin transfer // 2622012
FIELD: pharmacology.SUBSTANCE: treatment of wounds and skin cuts with a "Triderm" cream is shown without change of skin pigmentation, no burning or allergic reactions was observed; engraftment of a separated piece of skin is prescribed.EFFECT: cream or ointment creates conditions for tissue regeneration.2 cl
Pharmaceutical composition comprising luliconazole // 2621615
FIELD: pharmacology.SUBSTANCE: invention provides means to control the amount of the amide form, generated in a pharmaceutical composition containing luliconazole. The invention discloses pharmaceutical compositions containing 1) luliconazole and 2) one component, or two or more components selected from diisopropyl adipate, 1,3-butanediol, polyethylene glycol, propylene glycol and polypropylene glycol; wherein the content of the luliconazole amide derivative does not exceed 0.2 wt % of the luliconazole amount added to the composition, after storage at 60°C for 3 weeks or at 40°C for 6 months.EFFECT: improved luliconazole properties.6 cl, 8 tbl, 8 ex
ethod for neuralgia treatment // 2619344
FIELD: medicine.SUBSTANCE: for neuralgia treatment, a drug complex is used, where one of non-steroidal anti-inflammatory compounds drugs is applied as the basic analgesic agents, namely - ketorolac tromethamine at a dose of 15-75 mg, or sodium metamizole at a dose of 500-2500 mg, or the ketoprofen at a dose of 50-250 mg, or dexketoprofen at a dose of 25-125 mg, or lornoxicam at a dose of 4-20 mg, cyanocobalamin at a dose of 500-2500 mcg is used as an adjuvant analgesic agent, and drotaverine hydrochloride at a dose of 10-50 m is used as a myotropic spasmolytic action, that are administered intravenously with distribution of the said doses by one or two daily injectios, course of treatment lasts 1-10 days.EFFECT: method allows to ensure complete elimination of the pain syndrome after the course of treatment, the possibility of pain syndrome elimination with a single administration of drugs with obtaining of a momentary stable analgesic effect by eliminating the protective muscular tension in the affected nerve zone at method safety.2 tbl, 125 ex

Immunogenic compositions of multiple antigen presentation, methods and applications relating thereto // 2619176
FIELD: biotechnology.SUBSTANCE: immunogenic composition against one or more polysaccharide antigen, peptide antigen or polypeptide antigen comprises at least one antigenic polysaccharide, at least one peptide or polypeptide antigen and at least one complementary affinity molecules pair. At that, the first affinity molecule is associated with at least one antigenic polysaccharide, and the complementary affinity molecule is associated with at least one peptide or polypeptide antigen, wherein the said first affinity molecule binds to the complementary affinity molecule for the compound of peptide or polypeptide antigen and a polysaccharide antigen.EFFECT: invention allows to induce both humoral and cellular immune responses to one or multiple antigens simultaneously.20 cl, 40 dwg, 4 tbl, 4 ex

Pharmaceutical azoles preparation for parenteral injection and methods of production and application for treatment of diseases, sensitive to azole compounds // 2618456
FIELD: medicine, pharmacy.SUBSTANCE: invention includes an antifungal azole pharmaceutical agent - itraconazole or posaconazole, and a solvent, wherein the said solvent comprises a) an alcohol selected from benzyl alcohol and/or acidified ethanol and b) polyethylene glycol (PEG), at that, the azole agent is dissolved in the said solvent, wherein the composition is substantially free of nonionic surfactants and contains less than 5% of water. The invention also refers to the method for preparation of such a composition and its application for medicament preparation and the method for treatment of a patient with a disease responsive to an azole antifungal pharmaceutical agent comprising parenterally injection of a therapeutically effective volume of such composition to a patient.EFFECT: invention relates to a pharmaceutical composition suitable for parenteral injection.35 cl, 21 dwg, 11 tbl, 3 ex
Antimicrobial combination in terms of carbapenem resistantgram-negative pseudomonas aeruginosa bacteria, producing metal-β-lactamase // 2618433
FIELD: biotechnology.SUBSTANCE: invention describes jointly-used antimicrobial combinations of bisphosphonates and carbapenems against carbapenem-resistant gram-negative Pseudomonas aeruginosa ATCC 27853 bacteria, producing β metal-lactamase. Antimicrobial combination are characterized by the weight ratio of components, namely of a combination of imipenem/clodronic acid, meropenem/clodronic acid, imipenem/etidronic acid, meropenem/etidronic acid are used in ratios of 1:469, 1:3750, 1:25000, 1:25000, respectively.EFFECT: possibility of application to overcome resistance to carbapenems in gram-negative Pseudomonas aeruginosa ATCC 27853 bacteria.16 tbl

Pyrazole compound and its pharmaceutical use // 2617678
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to a compound of general formula or pharmaceutically acceptable salt thereof. In formula (I) Cy represents phenyl, C3-8 cycloalkyl or C3-8 cycloalkenyl , Cya is a heterocyclic group with the structure given in the invention formula, R1a and R2b are groups defined in the formula. The objects of invention are also the pharmaceutical composition and the agent based on formula (I) compound, the method of diabetes treatment and prevention and compound application.EFFECT: invention is SGLT1 inhibitor and can be used to treat or prevent diabetes.24 cl, 4 tbl, 605 ex
Pharmaceutical compositions comprising aromatase inhibitor // 2617510
FIELD: medicine, pharmacy.SUBSTANCE: this invention refers to low-dose pharmaceutical compositions comprising an aromatase inhibitor 4.4-'[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitril as an active ingredient in a suitable carrier. Furthermore, this invention refers to the process for their preparation and application as medicaments.EFFECT: invention expands the range of low-dose pharmaceutical compositions comprising the aromatase inhibitor.11 cl, 4 ex, 4 tbl
ethod for preparation of drug with amber acid and cetylpyridinium chloride with local action // 2617238
FIELD: pharmacology.SUBSTANCE: invention is a method for topical drug production for periodontal diseases treatment, comprising amber acid, cetyl pyridinium chloride, gelatin, glycerol, 1% solution of NaHCO3 and water, wherein the components are in a certain ratio per one film, in grams, including gelatin soaking in water, which is allowed to stand for 3 hours for swelling, and then heated in a water bath at 60°C until complete dissolution, at that, amber acid is dissolved in 1% solution of NaHCO3 and heated slightly to remove any air bubbles, then cetylpyridinium chloride and glycerol are added gradually to the resulting weight with stirring, and then the resulting solution is added to the cooled gelatin solution at continuous stirring, the mass stirred and left for 1 hour at room temperature to remove air, then a mould treated with 96% ethanol is filled with the resulting mass, which is spread evenly and allowed to stand for 72 hours at room temperature to dry and provide an elastic film.EFFECT: expansion of the arsenal of drugs with prolonged action.1 dwg, 1 tbl, 7 ex

Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt // 2616516
FIELD: pharmacy.SUBSTANCE: invention provides a pharmaceutical composition which is a single-dose dosage form comprising a compartment containing olmesartan medoxomil and a compartment comprising rosuvastatin or its salt, wherein the said compartments are formed in the isolated form. The compartment containing olmesartan medoxomil comprises from 7.5 to 65 wt % of hydroxypropylcellulose with a low degree of substitution. The compartment comprising rosuvastatin or its salt includes one or more disintegrants selected from the group consisting of crospovidone, hydroxypropyl cellulose with a low degree of substitution, croscarmellose sodium and carboxymethylcellulose calcium. The disintegrant in the said compartment with rosuvastatin is present in the amount of from 2 to 20 wt %. The pharmaceutical composition is a bilayer tablet or a capsule containing granules. The pharmaceutical composition of the present invention solves the problem of slowing down the absorption associated with drug-drug interactions.EFFECT: combination drug of the present invention is bioequivalent to mono-preparation of each of the said drugs.6 cl, 6 dwg, 16 tbl, 9 ex
Cycloalkanecarboxylic acid derivatives as cxcr3 receptor antagonists // 2615993
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula 1 where R is hydrogen or a C1-4-alkyl group; R1 means a group selected from the group consisting of structures represented by formulas (Ia), where R2 means hydrogen or a C1-4-alkyl group; R3 means hydrogen, a halogen, CF3, CN or C1-4-alkyl and R4 means hydrogen, a halogen or a C1-4-alkyl; a=0, 1, or 2; b=0, 1, 2 or 3; C=1, 2 or 3, and Ra, Rb, Rc and Rd represent, independently of one another, H or a C1-4-alkyl; X means a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a hetero-atom selected from O and S, or CH(CH2)CH-; Y means hydrogen, a halogen, a C1-4-alkyl, C1-4-alcoxy or C1-4-hydroxyalkyl; Z means a C1-4-aliphatic hydrocarbon bridge optionally containing one double bond and/or one hetero-atom selected from O, S, N and N(CH3), or means a C2-4-aliphatic hydrocarbon bridge fused with a C3-6-cycloalkyl, optionally containing one or more double bonds or with a phenyl ring, or means a C1-4-aliphatic hydrocarbon bridge substituted with a spiro-C3-6-cycloalkyl, optionally containing one or more double bonds; or its pharmaceutically acceptable salt, or a stereoisomer, or a pharmaceutically acceptable salt of the stereoisomer. The compounds according to the invention are obtained due to reductive amination of the benzaldehyde of formula 4 by means of a primary amine R1-NH2, the introduction in the interaction of the obtained secondary amine of formula 2 with ether formyl - or oxocyclohexanecarboxylic acid of formula 3, where X, Y, Z, R1, R, Ra, Rb, Rc, Rd, b and c have the meanings as specified for formula 1, and R' means -CHO or =O, and, optionally, the hydrolysis of the obtained ester of formula 1. The invention also relates to an intermediate compound of formula 2 or a salt thereof. The compound of formula 1 according to the invention is intended for use in the preventive and / or therapeutic treatment of a disease or disorder mediated by CXCR3 receptor as a medicament or as part of a pharmaceutical composition.EFFECT: cycloalkanecarboxylic acid derivatives as CXCR3 receptor antagonists.20 cl, 6 tbl, 160 ex
ethod for chronic periodontitis treatment // 2615271
FIELD: medicine.SUBSTANCE: stage-by-stage treatment combined with hypoxic-hypercapnic training for 20 minutes a day, 18-20 procedures in total. After 7-8 hypoxic-hypercapnic trainings against the maximum effect of periodontal tissues microcirculation improvement, local antibacterial, anti-inflammatory therapy and physical therapy is begun and continued together with hypoxic-hypercapnic training up to 5-6 sessions.EFFECT: exclusion of surgery and its complications, reduced volume of drugs, reduced terms of treatment, achievment of more stable and long-term remission due to improved microcirculation of periodontal tissues.2 cl, 1 ex

Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone // 2614978
FIELD: chemistry.SUBSTANCE: invention relates to a crystalline form of A (S)-1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulphonyl)ethanone.EFFECT: technical result is obtaining a crystalline form of A (S)-1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulphonyl)ethanone, as well as a veterinary composition and a method of treating parasitic infection or infestation with parasites in an animal in need thereof is described.13 cl, 7 dwg, 5 tbl, 3 ex
ethod for diffuse toxic goiter complex treatment // 2614850
FIELD: medicine.SUBSTANCE: for complex treatment of diffuse toxic goiter, antithyroid drugs are used. At that, the patient takes thyrozol and beta-blocker egiloc until thyroid status compensation according to the template. Then, at supporting thyrotropic therapy background, the patient additionally takes, together with the same drugs, an inhibitor of angiotensin converting enzyme fosicard, 10 mg or 20 mg per day continuously, and an antioxidant agent mexidol, 125 mg or 250 mg two times a day, by 2 months courses with equal intervals, 3 times in year. In addition, performance of the cardiovascular system functions is monitored.EFFECT: complex treatment of diffuse toxic goiter.1 tbl, 2 ex
3-methyl-1,2,4-triazole-5-thioacetate (s) -2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning // 2613875
FIELD: pharmacy.SUBSTANCE: 3-methyl-1,2,4-triazole-5-thioacetate (s)-2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning is proposed.EFFECT: highly effective prevention of central nervous system vital functions in case of preventive administration, adjustment of neurotoxic lesions in case of severe forms of acute ethanol poisoning, which in turn allows earlier restoration of the central nervous system vital functions and mortality reduction in case of acute ethanol poisoning.1 tbl
Ido inhibitors // 2613579
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, in particular, to derivatives of imidazo[5,1-a]isoindole of structure given below, or to a stereoisomer or pharmaceutically acceptable salt thereof, where bond α is a single or double bond; n = 0 or 1; R1: halogen or -OR; R2: -C1-4alkyl-RA or -C2-4alkenyl-R3, if bond α is a single bond; and R2: =C(H)RA, if bond α is a double bond; in which RA: -CN, -C(O)R3, -C(O)OR3, -C(O)N(R3)(RC), -C(ORB)(R3)(RC), -C(NHRB)(R3)(RC), or -C(=N-ORC)R3, where RB: hydrogen, -C(O)R3, -C(O)N(H)R3, -C(O)(CH2)2COOR, -C(O)(CH2)1-4(NR)COOR, -C(O)CH(NH2)(RD), or -P(O)(OR3)2; where RD: methyl or -CH(CH3)2; R3: hydrogen, C1-6alkyl, phenyl, imidazolyl, furanyl, thiazolyl, pyridinyl, C5-6cycloalkyl, C3-8cycloalkenyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, azetidinyl or C6cycloalkylC1alkyl-, where each alkyl, cycloalkyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl and azetidinyl is optionally and independently substituted with one group =R32 and optionally and independently substituted with one or two groups R31; each phenyl, imidazolyl, furanyl, thiazolyl and pyridinyl is optionally substituted with one or two groups R31; where R31: halogen, nitro, C1-6alkyl, -C1-6alkyl-R33, C1-6haloalkyl, -OR, -N(R)2, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)2R, -OC(O)R, -N(R)C(O)R or -N(R)C(O)OR, where R33: -OR; R32: =O, =C(R34)2, =(spiro-C3-8cycloalkyl), or =(spirodioxalanyl), where R34: hydrogen, halogen, C1-6alkyl or -C1alkyl-OR; RC: hydrogen or C1-6alkyl; and R: hydrogen or R10, where R10: C1-6alkyl, phenyl, thiophenyl, C5-6cycloalkyl, pyrrolidinyl, tetrahydropyranyl, phenylC1-6alkyl, heteroarylC1-2alkyl- (where heteroaryl group is a pyridine, pyrimidine or imidazole) or tetrahydropyranC1alkyl, where each of alkyl, phenyl, cycloalkyl and phenylC1-2alkyl optionally substituted with one or two groups, which independently represent a halogen, C1-6alkyl, C1haloalkyl, -OR11, -N(R11)2 or -N(R11)S(O)2R11, where R11: hydrogen or C1-6alkyl. Invention also relates to specific compounds, pharmaceutical composition based on declared imidazo[5,1-a]isoindole and a method of treating indoleamine-2,3-dioxygenase (IDO) mediated immunosuppression.EFFECT: novel derivatives of imidazo[5,1-a]isoindole are obtained, having useful biological properties.42 cl, 1 dwg, 75 ex
ethod of treating hyperkinetic syndrome in patients in vegetative state and minimally conscious state // 2613187
FIELD: medicine.SUBSTANCE: clonidine is introduced intravenously by microstream way in dose 0.2-1 mcg/kg/h. Simultaneously clonazepam is introduced in enteral way in dose 2-6 mg per day. Course of treatment is 7-14 days.EFFECT: method makes it possible to stop hyperkinetic syndrome in said group of patients effectively.2 ex
Agent for treatment of acute and chronic endometritis in cows // 2613141
FIELD: agriculture.SUBSTANCE: claimed invention relates to the field of veterinary medicine and is intended for treatment of acute and chronic endometritis in cows. The agent contains in its composition the substances of rifampicin, florfenicol, fluconazole, propylene glycol and purified water in the following ratios, % by weight: rifampicin 5, florfenicol 3, fluconazole 0.3, propylene glycol 30, the rest is purified water 61.7.EFFECT: invention enhances the therapeutic effect and reduces the treatment duration and frequency of the agent administration.4 tbl, 2 ex

Production method of metronidazole nanocapsules in konjac gum // 2613108
FIELD: nanotechnology.SUBSTANCE: metronidazole powder is added to konjac gum suspension in butanol and 0.01g of E472s, used as a surface-active substance, then 10 ml of carbon tetrachloride is added, the resulting suspension of nanocapsules is filtered and dried off, at that the weight ratio of core: shell in nanocapsules is 1:3, 1:1, 1:5 or 5:1.EFFECT: metronidazole nanocapsules production process simplification and acceleration, and also the weight yield increase.2 dwg, 5 ex
2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors // 2612958
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to a novel 2-pyridyl-substituted imidazole derivative of formula (I), where R1 is phenyl, pyridyl or thienyl, condensed with a structural fragment, which together with two ring members of said phenyl, pyridyl or thienyl forms a 5-6-member aromatic or non-aromatic saturated ring, wherein said ring optionally contains up to two heteroatoms, independently selected from O, N and S, and condensed phenyl ring is optionally substituted with one group, independently selected from halogen, -O-C-1-6alkyl, -C1-6alkyl, -O-(CH2)q-NR4R5, or 5-member heteroaryl containing up to two heteroatoms, independently selected from N; or R1 is phenyl, substituted with one or more groups, independently selected from halogen, -O-C1-6alkyl, -S-C1-6alkyl, -C1-6alkyl, -C1haloalkyl, -CN, -(CH2)p-NR4R5, -(CH2)p-NHCOR4, -(CH2)p-NHCO2R4; -(CH2)p-NHSO2R4 or N-bound 6-member heterocycle, where said heterocycle comprises two heteroatoms, independently selected from O, N, and optionally substituted with C1-6alkyl; R2 is -C1-6alkyl; R3 is H, -(CH2)p-NR4R5, -(CH2)p-CN, -(CH2)p-CO2R4, -(CH2)p-CONR4R5, -(CH2)p-OR4, -(CH2)p-NHCOR4; R4 and R5 independently denote H or -C1-6alkyl; p denotes an integer ranging from 0 to 1; q denotes 2; n denotes an integer ranging from 1 to 2; X is NR7; and R7 is H or -CO-C1-6alkyl. Invention also relates to use of a compound of formula (I), a pharmaceutical composition based on compound of formula (I) and to a method of preventing or treating diseases, based on use of compound of formula (I).EFFECT: technical result is obtaining novel heterocyclic compounds effective in treating or preventing a disease, mediated by ALK5 and/or ALK4 receptors in a mammal.8 cl, 44 ex, 1 tbl

Agent improving process of training, memory and cognitive functions, as well as for symptomatic therapy at autistic disorders // 2612791
FIELD: pharmaceutics.SUBSTANCE: invention relates to agent with nootropic and anti-autistic activity, representing tetrazole-containing derivative of 4-amino-3-phenyl-butyric acid of general formula (I): in which X=O, N, R2=H, CH3, X=O, R1=methyl, ethyl, H, X=N, R1=2-(pyridin-4-yl)ethyl, isopropyl. Invention also relates to pharmaceutical composition, medicinal agent and method of improving training processes, memory, cognitive functions.EFFECT: technical result: obtaining agent effective in treating disorders of cognitive functions, as well as for symptomatic therapy at autistic disorders.4 cl, 3 dwg, 16 tbl, 16 ex
Amide derivative and use of same as stability index of a luliconazole pharmaceutical formulation // 2612557
FIELD: chemistry.SUBSTANCE: invention relates to an amide derivative of luliconazole, of chemical formula (1): . Invention also relates to a method for assessing stability of a pharmaceutical composition of luliconazole, method of selecting a component of pharmaceutical formulation for pharmaceutical composition of luliconazole, method of preparing a pharmaceutical composition containing luliconazole, method of preparing a pharmaceutical composition of luliconazole.EFFECT: technical result is obtaining a novel amide derivative of luliconazole, which can be used as a stability index of a pharmaceutical composition containing luliconazole.8 cl, 4 tbl, 5 ex

Novel crystalline forms of sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)pyridin-2-yl]phenyl}cyclohexyl) acetic acid // 2612556
FIELD: chemistry.SUBSTANCE: invention relates to a crystalline form of a sodium salt (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)pyridin-2-yl] phenyl} cyclohexyl) acetic acid of formula (II) in form of Modification C, where said Modification C is characterised by x-ray powder diffraction pattern, including two, four or more 2θ values (±0.1 degree) (CuKα λ=1.5418 Å), selected from a group comprising values 5.9, 17.0, 19.6, 22.5, 23.6, 26.4, 26.8, 28.4 and 30.0, at temperature of approximately 22 °C.EFFECT: can be used in treating or preventing a condition or disorder, associated with DGAT1 activity.15 cl, 8 dwg, 33 tbl, 21 ex

Ester prodrugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol // 2612351
FIELD: chemistry.SUBSTANCE: invention relates to specific derivatives of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol. The invention also relates to specific intermediates, and pharmaceutical compositions based on the [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol derivative.EFFECT: new heterocyclic derivatives are obtained useful for treatment of conditions mediated by adrenergic receptors.4 cl, 2 dwg, 3 tbl, 13 ex
Pharmaceutical compositions // 2612022
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. Pharmaceutical composition for increasing salivation is described, containing multiple granules. Above granule contains core, first and second layers. Core contains cellulose polymer, silicon dioxide or sugar, selected from group, consisting of glucose, sucrose, lactose, mannitol, xylitol and sorbitol. First layer contains pilocarpine or its pharmaceutically acceptable salt. Second layer contains hydroxypropyl cellulose and ethyl cellulose in weight ratio of 1:1, wherein weight of second layer ranges from 75 % up to 250 % of granule weight before application of second layer.EFFECT: invention provides delayed immediate release of pilocarpine from pharmaceutical composition.10 cl, 14 tbl, 7 ex
Anthelmintic agent for treatment and prevention of fascioliasis, dicroceliosis and paramphistomatosis of cattle // 2612013
FIELD: agriculture.SUBSTANCE: invention relates to the field of veterinary medicine and is intended for treatment and prevention of trematode infections of liver (fascioliasis, dicroceliosis) and of proventriculi (paramphistomatosis) in cattle. The claimed anthelmintic agent comprises albendazole 10%, phenbendazol-(5-phenyl-thio-2-benzimidazole carbamate), an energy and bactericidal component - mepatar, the filler - propylene glycol iodised table salt, 10%), the fresh dead lime suspension, a filler and a prolongator - aqueous 20% suspension of bentonite. The agent is characterized in the fact that it is made in the form of a suspension.EFFECT: proposed agent is highly effective for treatment and prevention of fascioliasis, dicroceliosis and paramphistomatosis of cattle.3 tbl, 3 ex
Pharmaceutical composition possessing therapeutic effect on demyelinating diseases (versions) // 2611415
FIELD: chemistry.SUBSTANCE: present invention relates to chemical-pharmaceutical industry and medicine, particularly treating demyelinating diseases. Disclosed is a pharmaceutical composition in solid dosage form, having therapeutic effect on demyelinating disease, particularly multiple sclerosis, containing as an active substance biotin and target additives in certain proportions.EFFECT: composition is stable during storage for not less than 2,5 and has high bioavailability.9 cl, 1 tbl, 2 ex

ethod of production of metronidazole nanocapsules in sodium alginate // 2611368
FIELD: nanotechnology.SUBSTANCE: metronidazole powder is added to sodium alginate suspension in hexane and 0.01 g of E472s then acetone is added, the obtained suspension is filtered and dried. The mass ratio core:shell in nanocapsules is 1:3, 1:1, 1:5 or 5:1.EFFECT: nanocapsules of metronidazole manufacture process simplification and acceleration and weight yield increase.1 dwg, 5 ex
 
2551348.
Up!